Hepatopulmonary syndrome future or investigational therapies: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 3: Line 3:
{{CMG}}; {{AE}} {{Soroush}}
{{CMG}}; {{AE}} {{Soroush}}
==Overview==
==Overview==
rfloxacin, Pentoxifylline, inhaled N(G)-nitro-L-arginine methyl ester, nitric oxide inhalation and methylene blue injection, are among suggested and stuidied medical treatments for HPS.  
Norfloxacin, pentoxifylline, inhaled N(G)-nitro-L-arginine methyl ester, nitric oxide inhalation and methylene blue injection, are among suggested and studied medical treatments for HPS.  
==Future or Investigational Therapies==
==Future or Investigational Therapies==
*Nevertheless, Norfloxacin, Pentoxifylline, inhaled N(G)-nitro-L-arginine methyl ester, nitric oxide inhalation and methylene blue injection, are among suggested and stuidied medical treatments for HPS. Non of them yet approved as standard treatment for HPS.  
*Norfloxacin, pentoxifylline, inhaled N(G)-nitro-L-arginine methyl ester, nitric oxide inhalation and methylene blue injection, are among suggested and studied medical treatments for HPS. Non of them yet approved as standard treatment for HPS.
 
<ref name="pmid20816858">Gupta S, Faughnan ME, Lilly L, Hutchison S, Fowler R, Bayoumi AM (2010) [https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&retmode=ref&cmd=prlinks&id=20816858 Norfloxacin therapy for hepatopulmonary syndrome: a pilot randomized controlled trial.] ''Clin Gastroenterol Hepatol'' 8 (12):1095-8. [http://dx.doi.org/10.1016/j.cgh.2010.08.011 DOI:10.1016/j.cgh.2010.08.011] PMID: [https://pubmed.gov/20816858 20816858]</ref>
<ref name="pmid20816858">Gupta S, Faughnan ME, Lilly L, Hutchison S, Fowler R, Bayoumi AM (2010) [https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&retmode=ref&cmd=prlinks&id=20816858 Norfloxacin therapy for hepatopulmonary syndrome: a pilot randomized controlled trial.] ''Clin Gastroenterol Hepatol'' 8 (12):1095-8. [http://dx.doi.org/10.1016/j.cgh.2010.08.011 DOI:10.1016/j.cgh.2010.08.011] PMID: [https://pubmed.gov/20816858 20816858]</ref>
<ref name="pmid18779471">Gupta LB, Kumar A, Jaiswal AK, Yusuf J, Mehta V, Tyagi S et al. (2008) [https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&retmode=ref&cmd=prlinks&id=18779471 Pentoxifylline therapy for hepatopulmonary syndrome: a pilot study.] ''Arch Intern Med'' 168 (16):1820-3. [http://dx.doi.org/10.1001/archinte.168.16.1820 DOI:10.1001/archinte.168.16.1820] PMID: [https://pubmed.gov/18779471 18779471]</ref>
<ref name="pmid18779471">Gupta LB, Kumar A, Jaiswal AK, Yusuf J, Mehta V, Tyagi S et al. (2008) [https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&retmode=ref&cmd=prlinks&id=18779471 Pentoxifylline therapy for hepatopulmonary syndrome: a pilot study.] ''Arch Intern Med'' 168 (16):1820-3. [http://dx.doi.org/10.1001/archinte.168.16.1820 DOI:10.1001/archinte.168.16.1820] PMID: [https://pubmed.gov/18779471 18779471]</ref>

Revision as of 15:11, 5 September 2019

Hepatopulmonary syndrome Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Hepatopulmonary syndrome from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Interventions

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Hepatopulmonary syndrome future or investigational therapies On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Hepatopulmonary syndrome future or investigational therapies

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Hepatopulmonary syndrome future or investigational therapies

CDC on Hepatopulmonary syndrome future or investigational therapies

Hepatopulmonary syndrome future or investigational therapies in the news

Blogs on Hepatopulmonary syndrome future or investigational therapies

Directions to Hospitals Treating Psoriasis

Risk calculators and risk factors for Hepatopulmonary syndrome future or investigational therapies

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Soroush Seifirad, M.D.[2]

Overview

Norfloxacin, pentoxifylline, inhaled N(G)-nitro-L-arginine methyl ester, nitric oxide inhalation and methylene blue injection, are among suggested and studied medical treatments for HPS.

Future or Investigational Therapies

  • Norfloxacin, pentoxifylline, inhaled N(G)-nitro-L-arginine methyl ester, nitric oxide inhalation and methylene blue injection, are among suggested and studied medical treatments for HPS. Non of them yet approved as standard treatment for HPS.

[1] [2] [3] [4] [5] [6]

References

  1. Gupta S, Faughnan ME, Lilly L, Hutchison S, Fowler R, Bayoumi AM (2010) Norfloxacin therapy for hepatopulmonary syndrome: a pilot randomized controlled trial. Clin Gastroenterol Hepatol 8 (12):1095-8. DOI:10.1016/j.cgh.2010.08.011 PMID: 20816858
  2. Gupta LB, Kumar A, Jaiswal AK, Yusuf J, Mehta V, Tyagi S et al. (2008) Pentoxifylline therapy for hepatopulmonary syndrome: a pilot study. Arch Intern Med 168 (16):1820-3. DOI:10.1001/archinte.168.16.1820 PMID: 18779471
  3. Tanikella R, Philips GM, Faulk DK, Kawut SM, Fallon MB (2008) Pilot study of pentoxifylline in hepatopulmonary syndrome. Liver Transpl 14 (8):1199-203. DOI:10.1002/lt.21482 PMID: 18668653
  4. Brussino L, Bucca C, Morello M, Scappaticci E, Mauro M, Rolla G (2003) Effect on dyspnoea and hypoxaemia of inhaled N(G)-nitro-L-arginine methyl ester in hepatopulmonary syndrome. Lancet 362 (9377):43-4. DOI:10.1016/S0140-6736(03)13807-X PMID: 12853200
  5. Schenk P, Madl C, Rezaie-Majd S, Lehr S, Müller C (2000) Methylene blue improves the hepatopulmonary syndrome. Ann Intern Med 133 (9):701-6. DOI:10.7326/0003-4819-133-9-200011070-00012 PMID: 11074903
  6. Jounieaux V, Leleu O, Mayeux I (2001) Cardiopulmonary effects of nitric oxide inhalation and methylene blue injection in hepatopulmonary syndrome. Intensive Care Med 27 (6):1103-4. PMID: 11497151

Template:WH Template:WS